Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 31

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Brain injury

Recruiting

Study of Brain Injury and Concussion Symptoms Using Tau Tracer [18F]RO6958948 in Patients with Traumatic Brain Injury and Hemorrhages

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3',4'-D]Pyrrole
  • Sponsor:Region Skane

Glycogen storage disease type II

Recruiting

Study on the Safety and Effects of SPK-3006 for Adults with Late-Onset Pompe Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vanglusagene Ensiparvovec
  • Sponsor:Genentech Inc.

Autism spectrum disorder

Recruiting

Study on Oxytocin Treatment for Children with Autism and Intellectual Disability

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

Anaesthesia

Recruiting

Study on the Effects of Ropivacaine and Lidocaine in Patients Receiving Cardiac Device Implants

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lidocaine Hydrochloride
  • Sponsor:Medizinische Universitaet Innsbruck

Central nervous system lymphoma+4

Recruiting

Study on Golcadomide and Valemetostat Tosylate for Patients with Relapsed or Refractory Non-Hodgkin Lymphomas

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:Celgene Corp.

Neuroblastoma

Recruiting

Study Comparing [18F]meta-fluorobenzylguanidine PET-CT and Iodine (123I) Iobenguane Scans for Detecting Neuroblastoma in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:[18F]Meta-Fluorobenzylguanidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Autism spectrum disorder

Recruiting

Study on Arbaclofen for Improving Social Function in Children and Adolescents with Autism Spectrum Disorder

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Arbaclofen
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon

Parkinson's disease

Recruiting

Study on Ambroxol and Clenbuterol for Early Parkinson's Disease in Patients with GBA1 Mutation

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ambroxol Hydrochloride
  • Sponsor:Universitair Medisch Centrum Groningen

Subdural haematoma

Recruiting

Study on Tranexamic Acid to Prevent Surgery in Patients with Chronic Subdural Hematoma

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tranexamic Acid
  • Sponsor:Amsterdam UMC Stichting

Foetal exposure during pregnancy+2

Recruiting

Study of Metformin to Extend Pregnancy Duration in Women with Preterm Preeclampsia

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Metformin Hydrochloride
  • Sponsor:Amsterdam UMC Stichting

Haemorrhagic stroke

Recruiting

Study on Eptacog Alfa for Treating Acute Hemorrhagic Stroke in Patients with Brain Bleeding

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Eptacog Alfa (Activated)
  • Sponsor:University Of Cincinnati College Of Medicine

Tardive dyskinesia

Recruiting

Study on the Effects of (+)-α-Dihydrotetrabenazine for Patients with Moderate to Severe Tardive Dyskinesia

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:(2R,3R,11Br)-1,3,4,6,7,11B-Hexahydro-9,10-Dimethoxy-3-(2-Methylpropyl)-2H-Benzo[A]Quinolizin-2-Ol
  • Sponsor:Adeptio Pharmaceuticals Limited

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.